Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

The weeks following a launch are for intense learning, not just promotion. The goal is to quickly identify high-adopting customer segments and then execute mini 'relaunches' with tailored messaging specifically for them, maximizing impact and conversion.

While launching a first-in-class drug is an achievement, true marketing excellence is shown when a team successfully launches a product that is second, third, or fourth to market. This requires superior execution and strategy to overcome established competitors with fewer resources.

Treat your startup like a drug discovery experiment. A market's needs are like biological 'binding receptors'—they either exist or they don't. Marketing can raise awareness of your 'drug' (product), but it can't convince the body to grow new receptors. If you lack product-market fit, don't try to market your way out of it.

Timing a key data readout is critical for a newly public biotech. A readout in under three months is too soon, as investors will simply wait for the results before buying. Waiting longer than a year risks losing market relevance. The optimal window to maintain momentum is 6-12 months post-IPO.

Don't treat validation as a one-off task before development. The most successful products maintain a constant feedback loop with users to adapt to changing needs, regulations, and tastes. The worst mistake is to stop listening after the initial launch, as businesses that fail to adapt ultimately fail.

Don't get distracted by the vague goal of "achieving product-market fit." Instead, focus on tangible, measurable signals of traction: Are people buying the product? Is the messaging resonating? Do you have the right sales funnel? These concrete metrics provide actionable feedback that leads to success.

Beyond massive upfront investment and high failure rates, the most uncontrollable risk in a blockbuster strategy is timing, or luck. A revolutionary product launched before the market is ready for it is functionally a failure, regardless of its quality or innovation.

Achieving product-market fit isn't a permanent milestone. The moment you find it, market dynamics and customer expectations cause it to "drift." This requires continuous effort to maintain alignment, making it an ongoing process rather than a finish line to be crossed and forgotten.